^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
precemtabart tocentecan (M9140)
i
Other names: M9140, M-9140, M 9140, Precem-TcT
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
EMD Serono
Drug class:
Topoisomerase I inhibitor, CEACAM5-targeted antibody-drug conjugate
Related drugs:
2d
MS202329_0010: Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) (2024-517817-34-00)
P1/2, N=45, Active, not recruiting, Merck Healthcare KGaA | Recruiting --> Active, not recruiting
Enrollment closed • Pan tumor
|
HER-2 (Human epidermal growth factor receptor 2) • CEACAM5 (CEA Cell Adhesion Molecule 5)
|
HER-2 negative
|
precemtabart tocentecan (M9140)
2d
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) (clinicaltrials.gov)
P1/2, N=250, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Recruiting --> Active, not recruiting | Active, not recruiting --> Recruiting
Enrollment closed • Enrollment open • Pan tumor
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • CEACAM5 (CEA Cell Adhesion Molecule 5)
|
EGFR mutation • HER-2 negative • EGFR expression
|
precemtabart tocentecan (M9140)
7d
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) (clinicaltrials.gov)
P3, N=1020, Not yet recruiting, EMD Serono Research & Development Institute, Inc.
New P3 trial
|
Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • precemtabart tocentecan (M9140)
8d
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (clinicaltrials.gov)
P1, N=200, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Feb 2027 --> Oct 2026 | Trial primary completion date: Feb 2027 --> Oct 2026
Trial completion date • Trial primary completion date • First-in-human
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Avastin (bevacizumab) • 5-fluorouracil • capecitabine • leucovorin calcium • precemtabart tocentecan (M9140)
8d
Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors (clinicaltrials.gov)
P1, N=12, Active, not recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2026 --> Sep 2026
Trial completion date • Trial primary completion date
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
MSI-H/dMMR • BRAF wild-type
|
precemtabart tocentecan (M9140)
2ms
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (clinicaltrials.gov)
P1, N=200, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Aug 2026 --> Feb 2027 | Trial primary completion date: Aug 2026 --> Feb 2027
Trial completion date • Trial primary completion date • First-in-human
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Avastin (bevacizumab) • 5-fluorouracil • capecitabine • leucovorin calcium • precemtabart tocentecan (M9140)
4ms
Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors (clinicaltrials.gov)
P1, N=12, Active, not recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Recruiting --> Active, not recruiting | N=24 --> 12
Enrollment closed • Enrollment change
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
MSI-H/dMMR • BRAF wild-type
|
precemtabart tocentecan (M9140)
9ms
Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial. (PubMed, Nat Med)
Precemtabart tocentecan (Precem-TcT, previously M9140) is an anti-CEACAM5 antibody-drug conjugate with the topoisomerase 1 inhibitor exatecan as payload...In the dose-escalation stage of the phase 1 trial of Precem-TcT (PROCEADE-CRC-01), 40 heavily pretreated patients with irinotecan-refractory metastatic CRC received Precem-TcT every 3 weeks across seven dose levels (DLs, 0.6-3.2 mg kg-1)...The dose-optimization part at the RDEs of 2.4 mg kg-1 and 2.8 mg kg-1 (both every 3 weeks) in PROCEADE-CRC-01 is ongoing. ClinicalTrials.gov identifier: NCT05464030 .
P1 data • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
irinotecan • precemtabart tocentecan (M9140)
9ms
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (clinicaltrials.gov)
P1, N=200, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Feb 2026 --> Aug 2026
Trial completion date • Trial primary completion date
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Avastin (bevacizumab) • 5-fluorouracil • capecitabine • leucovorin calcium • precemtabart tocentecan (M9140)
10ms
Anti-CEACAM5 ADC M9140 in Chinese Participants With Solid Tumors (PROCEADE-CRC-02) (clinicaltrials.gov)
P1, N=24, Recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Trial completion date: Aug 2026 --> May 2026
Trial completion date
|
precemtabart tocentecan (M9140)
10ms
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) (clinicaltrials.gov)
P1/2, N=250, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Jan 2029 --> Jan 2028 | Trial primary completion date: Jan 2029 --> Jan 2028
Trial completion date • Trial primary completion date • Pan tumor
|
precemtabart tocentecan (M9140)
1year
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) (clinicaltrials.gov)
P1/2, N=250, Recruiting, EMD Serono Research & Development Institute, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
precemtabart tocentecan (M9140)
Share via
